Oncoprotein C-MYC is overexpressed in human metastatic melanomas and melanoma-derived cells where it is required for the suppression of oncogene-induced senescence (OIS). The genetic events that maintain high levels of C-MYC in melanoma cells and their role in OIS are unknown. Here we report that C-MYC in cells from several randomly chosen melanoma lines was upregulated at the protein level, and largely because of the increased protein stability. Of all known regulators of C-MYC stability, levels of B56a subunit of the PP2A tumor suppressor complex were substantially suppressed in all human melanoma cells compared with normal melanocytes. Accordingly, immunohistochemical analysis revealed that the lowest and the highest amounts of PP2A-B56a were predominantly detected in metastatic melanoma tissues and in primary melanomas from patients with good clinical outcome, respectively. Importantly, PP2A-B56a overexpression suppressed C-MYC in melanoma cells and induced OIS, whereas depletion of PP2A-B56a in normal human melanocytes upregulated C-MYC protein levels and suppressed BRAF V600E -and, less efficiently, NRAS Q61R -induced senescence. Our data reveal a mechanism of C-MYC overexpression in melanoma cells and identify a functional role for PP2A-B56a in OIS of melanocytic cells.
Introduction
Oncogene-induced senescence (OIS) is a mechanism for the suppression of tumor growth at the pre-neoplastic stage (Bringold and Serrano, 2000; Mooi and Peeper, 2006; Bansal and Nikiforov, 2010) . One of the best examples of naturally occurring OIS in humans is the nevus, a benign aggregation of non-proliferative melanocytes that often harbor activating mutations in BRAF, NRAS or HRAS genes (Pollock et al., 2003; Michaloglou et al., 2005; Gray-Schopfer et al., 2007) . Intriguingly, activating mutations in the same genes have been detected in several types of malignant melanomas but at lower frequencies (Maldonado et al., 2003; Pollock et al., 2003; Curtin et al., 2005) , indicating that malignant melanomas that often originate from nevi must have developed mechanisms that circumvent OIS. Ectopic expression of the activated forms of the above oncogenes (BRAF V600E , NRAS Q61R , HRAS G12V ) in normal human melanocytes (NHMs) also induced senescence (Pollock et al., 2003; Denoyelle et al., 2006) , which was not prevented by individual depletion of such tumor suppressor genes as p53, p16
INK4A (Denoyelle et al., 2006; Zhuang et al., 2008) , p21 CIP/WAF or p14 ARF (Haferkamp et al., 2009) . Instead, ectopic expression of the oncogenic transcription factor C-MYC has been shown to significantly suppress senescence phenotypes caused by BRAF V600E and, to much lesser extent, by NRAS Q61R in NHM .
C-MYC is a member of the MYC family of oncoproteins (Grandori et al., 2003; Nikiforov et al, 2003) . It regulates the expression of >3000 genes involved in a large variety of cellular processes including the cell cycle regulation (Henriksson and Lu¨scher, 1996) , differentiation (Eilers, 1999) , metabolism Dang et al., 2009) , apoptosis (Nilsson and Cleveland, 2003; Meyer et al., 2006) and senescence (Wu et al., 2007; Zhuang et al., 2008; Hydbring et al, 2010) . C-MYC is required for the proliferation of all tested human cells (Wang et al., 2008) , and is frequently upregulated in human malignancies including metastatic melanoma (Nesbit et al., 1999) . In cells from solid tumors, the elevated expression of C-MYC can be maintained through several mechanisms including gene amplification (Nesbit et al., 1999) , enhanced capdependent and cap-independent translation of C-MYC mRNA (De Benedetti and Graff, 2004; Shi et al., 2008) and elevated protein stability (Hann, 2006) . C-MYC stability is regulated in part by post-translational modifications on its two highly conserved residues: phosporylation of Ser 62 by the RAS-RAF-MEK-ERK kinase cascade stabilizes C-MYC (Lutterbach and Hann, 1994; Sears et al., 1999) , whereas phopshorylation of Thr 58 by GSK3b kinase promotes C-MYC proteosomal degradation (Gregory and Hann, 2000; Bahram et al., 2000) . C-MYC phosphorylated on Thr 58 is recognized by FBW7, a receptor component of the ubiquitin-ligase complex, Skp2-Cullin-F-box, and is subsequently ubiquitinated (Kim et al., 2003; Welcker et al., 2004) . MYC phosphorylated at Ser 62 /Thr 58 is also recognized by the prolylisomerase Pin1 that induces conformational changes at the peptide bond between Ser 62 and Pro 63 and facilitates interactions between phosphorylated Ser 62 and a serine/threonine phosphatase complex PP2A (Arnold and Sears, 2006) . PP2A dephosphorylates phospho-Ser 62 of C-MYC thus promoting its degradation. PP2A consists of a structural subunit (A), catalytic subunit (C), and one of multiple regulatory subunits (B) that specify PP2A target binding (Arroyo and Hahn, 2005) . The B56a regulatory subunit of PP2A has been shown to interact with C-MYC, enhance dephosphorylation of phospho-Ser 62 and promote C-MYC degradation (Arnold and Sears, 2006) . Depletion of PP2A-B56a cooperated with SV40T antigen, catalytic subunit of telomerase reverse transcriptase and HRAS G12V in transformation of human kidney epithelial cells (Sablina et al., 2010 ). Yet, unlike other protein controlling C-MYC stability (Rajagopalan et al., 2004; Vaarala et al., 2010) , deregulated expression of PP2A-B56a has never been associated with any human malignancies.
Other proteins regulating C-MYC stability include: CIP2A, a C-MYC-interacting protein that specifically inhibits PP2A activity against C-MYC (Junttila et al., 2007) ; USP28, a de-ubiquitinating enzyme that antagonizes FBW7 and promotes C-MYC stability (Popov et al., 2007) and TRUSS, a receptor for DDB1 (damage-specific DNA-binding protein 1)-Cullin 4 E3 ligase complex (Choi et al., 2010) .
Recently, we have demonstrated that short hairpin RNA (shRNA)-mediated depletion of C-MYC in metastatic melanoma cells resulted in the re-emergence of senescence phenotypes that were characteristic for NHM ectopically expressing BRAF V600E or NRAS Q61R . The mechanisms maintaining high levels of C-MYC in melanoma cells and their role in suppression of OIS remain unknown. To answer this question, we report here that increased protein stability has a major role in maintaining high amounts of C-MYC in melanoma cells and that PP2A-B56a represents a key regulator of C-MYC protein stability and OIS in normal and transformed melanocytic cells.
Results

C-MYC abundance in human melanoma cells is maintained at the protein level
To investigate mechanisms underlying overexpression of C-MYC in melanoma cells, we analyzed C-MYC protein and mRNA levels in cells from seven arbitrarily chosen melanoma lines derived from human melanoma metastases and two independently isolated populations S-methionine/ 35 S-cysteine (300 mCi/ml, Perkin-Elmer) in the cysteine/methionine-free media for 3 h and 1 h, respectively, for 0, 20, 40 or 60 min. After completion of incubation, cells were lysed and total cellular extracts were immunoprecipitated with mouse anti-C-MYC antibodies. Immunoprecipitated materials were separated on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and labeled C-MYC was quantified using STORM phospho-imager. After background subtraction, band intensity was plotted on a log scale for each time point using Microsoft Excel graphing function, and C-MYC half-life was determined from the graph.
PP2A-B56a promotes oncogene-induced senescence S Mannava et al of NHM. C-MYC protein levels were B4 to 11 times higher in melanoma cells compared with NHM (Figure 1a ), whereas C-MYC mRNA amounts in melanoma cells were at most 2.5-fold higher than that of NHM (Figure 1b) . These data suggest that the high amounts of C-MYC in studied melanoma cells could be due to the increased protein stability or elevated translational rates of its mRNA. To test the former possibility, C-MYC protein half-life was assessed in a population of NHM (designated as 'b' on Figure 1a ) and in cells from three arbitrary chosen melanoma cell lines, SK-Mel-19, SK-Mel-29, SK-Mel-147, in pulsechase 35 S-methionine/cysteine labeling assay. As shown in Figure 1c , C-MYC protein half-life was 2.6-to 7.3-fold higher in melanoma cells than in NHM indicating that C-MYC protein is more stable in melanoma cells compared with NHM.
Several polypeptides were implicated in the control of C-MYC protein stability: PP2A-B56a; PP2A-C; FBW7-a, -b, -g; PIN1; SKP2; CIP2A; TRUSS and USP28. We examined the expression of these polypeptides in NHM and melanoma cells by western blotting. Surprisingly, expression of only two of these proteins, PP2A-B56a and CIP2A, differed dramatically between NHM and all melanoma cells (Figure 2a ). PP2A-B56a was acutely suppressed in melanoma cells compared with NHM, whereas CIP2A demonstrated directly the opposite expression pattern. Interestingly, the expression of PP2A-C, a catalytic subunit of PP2A complex, did not change among the studied cells.
CIP2A has been recently characterized as a direct target of C-MYC gene (Khanna et al., 2009) , whereas ability of C-MYC to regulate PP2A-B56a has never been investigated. To address this question, we depleted C-MYC in cells from two arbitrarily chosen melanoma lines via shRNA (Wang et al., 2008) and monitored expression of CIP2A and PP2A-B56a by western blotting at 6 days post infection. Depletion of C-MYC substantially affected levels of CIP2A, but not PP2A-B56a (Figure 2b ), indicating that PP2A-B56a expression does not depend on C-MYC in studied melanoma cells.
To validate the expression pattern of PP2A-B56a observed in cultured cells, we analyzed its protein levels immunohistochemically in tissue microarrays (TMAs) containing 56 primary cutaneous melanomas from the individuals with good clinical outcome (in lieu of TMA containing adequate number of samples from benign melanocytic nevi) and 167 metastatic melanoma specimens (Table 1) Staining intensity scores are as follows: no staining (0), weak staining (1), moderate staining (2) and strong staining (3).
PP2A-B56a promotes oncogene-induced senescence S Mannava et al expression of PP2A-B56a (intensity score 3; >50% of cells stained) were 12.22 times more frequent in TMAs derived from primary tumors compared with metastases (P ¼ 0.0237), whereas cores with the lowest expression of PP2A-B56a (intensity score 0) were 3.71 times more likely to be derived from metastatic samples than primary tumors (P ¼ 0.0242). Representative cores from each group are shown in Figure 2c . These results confirm our observations made in cultured cells that PP2A-B56a is downregulated during melanoma progression. (Figure 3d ). It is noteworthy that in cells from all lines the senescence-associated phenotypes induced by PP2A-B56a overexpression were very similar to those caused by direct depletion of C-MYC via shRNAs . Therefore, ectopic expression of PP2A-B56a induces senescence in melanoma cells, although with different incubation period. Importantly, overexpression of PP2A-B56a in cells from three out of four tested lines (SK-Mel-19, -29 and -147) either did not affect C-MYC mRNA levels or depleted them roughly by B50% (Figure 3b ), demonstrating that PP2A-B56a controls C-MYC in melanoma cells predominantly at the protein level.
PP2A-B56a suppresses C-MYC in melanoma cells and induces senescence-like phenotypes
Depletion of PP2A-B56a in NHM leads to increased C-MYC levels and resistance to BRAF V600E -induced senescence and partial resistance to NRAS Q61R -induced senescence To identify whether C-MYC protein levels depend on endogenous PP2A-B56a, we infected NHM with lentiviral vectors containing two different shRNAs against PP2A-B56a or control shRNA. Cells were collected at 5 days post infection to assess changes in C-MYC and PP2A-B56a mRNA and protein levels. Each shRNA against PP2A-B56a efficiently depleted its mRNA and protein (Figures 3e and f) . Importantly, PP2A-B56a depletion resulted in 3.1-to 3.4-fold increase in the amounts of C-MYC protein, but not mRNA (Figures 3e and f) .
As B56a controls PP2A-dependent de-phosphorylation of C-MYC phospho-Ser 62 , we investigated the effect of shRNA-mediated depletion of PP2A-B56a on this modification of C-MYC. Using western blotting with antibodies specific to total or phospho-Ser 62 C-MYC, we detected an B50% increase in C-MYC protein phosphorylated on Ser 62 in PP2A-B56a-depleted cells (Figure 3e ), thus providing a mechanistic explanation to the increased C-MYC protein amounts.
To identify whether PP2A-B56a depletion overcomes OIS in NHM, first, these cells were infected with lentiviral vector expressing BRAF V600E or with empty lentiviral vector followed by superinfection with control or PP2A-B56a shRNAs. The functional activity of BRAF V600E in infected cells was confirmed by monitoring phosphorylation of ERK, a downstream target of activated RAS-RAF pathway (Figure 4a) . As has been shown previously , a significant decline in C-MYC amounts was observed in BRAF V600E -expressing melanocytes between days 10 and 15 post infection (Figure 4b) , concomitant with the strong manifestation of the senescence-associated phenotypes including reduction in proliferative rates (assessed by the 5-ethynyl-2 0 -deoxyuridine (EdU) incorporation) and the increase in the percentage of SA-b-Gal-positive cells and cells containing senescence-associated heterochromatin foci (Figures 4c and d) . Depletion of PP2A-B56a in BRAF V600E -expressing melanocytes prevented downregulation of C-MYC and the emergence of senescenceassociated phenotypes (Figures 4b-d ). These data demonstrate that suppression of PP2A-B56a has a functional role in overcoming BRAF (Figure 4b ). Interestingly, upregulation of C-MYC partially reversed senescence-associated phenotypes caused by NRAS Q61R but did not significantly suppress these phenotypes induced by HRAS G12V (Figures 4c and d) . Thus, in NHM, PP2A-B56a depletion differentially affects OIS induced by members of RAS family of proteins most commonly activated in melanocytic cells.
Discussion
In this manuscript, we present data arguing that protein stability is a major factor contributing to the elevated levels of C-MYC in melanoma cells. Furthermore, we demonstrate that among all known regulators of C-MYC stability, the expression of two proteins that regulate PP2A activity against C-MYC (CIP2A and PP2A-B56a) were markedly different between NHM and melanoma cells. Therefore, it is quite remarkable that despite high genetic variability of melanoma cells (Smalley et al., 2005) , C-MYC was similarly upregulated in cells from all studied melanoma lines and that the expression of two proteins regulating a single posttranslational modification of C-MYC (phosphorylation of Ser 62 ) was also, respectively, uniformed among these lines. In principal, this uniformity could be because of another feature common for all studied melanoma cells: the activated state of MEK-ERK pathway. Because Ser 62 is a target of ERK (Sears et al, 1999) , phosphorylation of Ser 62 can be a rheostat for the opposing activities of ERK and PP2A.
Activation of BRAF, NRAS or HRAS has a controversial role in melanomagenesis. On the one hand, constitutive activity of these oncoproteins is essential for sustained proliferation of melanoma cells, which requires high levels of C-MYC Welcker et al., 2004) . On the other hand, these oncogenes cause OIS in NHM accompanied by downregulation of C-MYC . Intriguingly, BRAF V600E stimulates proliferation shortly after delivery into NHM and suppresses it at later time points (Denoyelle et al., 2006; Zhuang et al., 2008) . Our previous and current data support the model that suppression of C-MYC is responsible for the transition from proliferation promoting to proliferation-inhibitory activities of BRAF V600E and possibly activated RAS proteins.
We report that overexpression of PP2A-B56a suppressed C-MYC protein rather than mRNA levels in cells from two out of four examined melanoma lines. In the other two lines (SK-Mel-19 and SK-Mel-103), PP2A-B56a overexpression led to 50 and 77% reduction in C-MYC mRNA, respectively. This phenomenon may be because of the reported ability of PP2A-B56a to facilitate degradation of b-catenin (Arnold et al., 2009; Hart et al., 1998) , a mediator of Wnt-pathway-dependent upregulation of C-MYC transcription (He et al., 1998) . Because the Wnt pathway is often activated in melanoma cells , HRAS G12V or NRAS Q61R complementary DNAs (cDNAs). Cells were collected at 3 days post infection, and total protein extracts were probed in western blotting with the antibodies designated on the left. (b) NHMs were infected with control lentiviral vector or vector expressing BRAF V600E cDNAs, followed by superinfection with control or PP2A-B56a shRNAs at 3 days after the first infection. Cells were collected at 12 days post second infection, and total protein extracts were probed in western blotting with the antibodies designated on the left; in parallel, NHM were infected with control or PP2A-B56a shRNAs followed by superinfection with control lentiviral vector or vectors expressing HRAS G12V or NRAS Q61R cDNA at 4 days after the first infection. Cells were collected at 6 days post second infection, and total protein extracts were probed in western blotting with the antibodies designated on the left. (c) At the indicated time points, NHM infected such as in b, were assayed for proliferation rates (EdU incorporation), or fixed and stained for SA-b-galactosidase activity (SA-b-Gal) or stained with 4 0 ,6-diamidino-2-phenylindole to visualize senescence-associated heterochromatin foci (SAHF). For 'EdU incorporation' number of positive cells was divided by the number of total cells and by the ratio of positive/total cells in control populations (CL/V). Asterisks (*) indicate statistically significant difference between values corresponding to CL/NRAS and B1/NRAS (P ¼ 0.0433) or CL/NRAS and B2/NRAS (P ¼ 0.0361). For 'SA-b-Gal', and 'SAHF' the non-normalized percentage of cells is shown. (d) NHM infected with the designated lentiviral vectors were fixed and stained for SA-b-Gal activity as described above (representative pictures are shown).
PP2A-B56a promotes oncogene-induced senescence S Mannava et al (Larue and Delmas, 2006) , including SK-Mel-103 (DZ and MAN, unpublished observations), the presumed degradation of b-catenin via PP2A-B56a in these cells may affect C-MYC mRNA levels.
PP2A-B56a-dependent depletion of C-MYC in studied melanoma cells resulted in the emergence of senescence phenotypes similar to those caused by depletion of C-MYC via shRNA. However, the timing of senescence varied substantially: 5-6 days post infection with PP2A-B56a in SK-Mel-19, -29 cells versus 14-20 days post infection in SK-Mel-103, -147 cells. In the latter group, the amounts of C-MYC did not change until before the emergence of senescence phenotypes (data not shown), indicating that ectopic PP2A-B56a in these cells did not suppress C-MYC amounts during a long period of time. One possible explanation for this observation is that unlike BRAF . OIS induced by NRAS Q61R was inhibited only partially, whereas HRAS G12V -dependent senescence phenotypes were unaffected by upregulation of C-MYC. These data are concordant with our previous observations that ectopic expression of C-MYC much more efficiently overcomes OIS caused by BRAF V600E than by NRAS Q61R . Unlike BRAF
V600E
, HRAS G12V and, to much lesser extent, NRAS Q61R induce the unfolded protein response in NHM (Denoyelle et al., 2006) . In our experience, C-MYC overexpression in NHM does not suppress the unfolded protein response pathway , which could account for the inability of PP2A-B56a depletion and subsequent C-MYC upregulation to overcome HRAS G12V -induced senescence in these cells. In summary, we demonstrated that increased protein stability contributes substantially to the elevated levels of C-MYC in melanoma cells. We showed that PP2A-B56a can account for differential C-MYC expression between NHM and melanoma cells. Lastly, we demonstrated the functional importance of PP2A-B56a downregulation for both the maintenance of high levels of C-MYC and the suppression of OIS in NHM and melanoma cells.
Materials and methods
Cell lines
Melanoma cell lines were originally obtained from Memorial Sloan Kettering Cancer Center. Cells were cultured in Dulbecco's modified Eagle's essential minimal medium as recommended by the supplier. Supplements included fetal calf serum (10%), 2 mM glutamine and 100 U/ml penicillin G þ 100 mg/ml streptomycin. All cell culture agents were purchased from Invitrogen Inc. (Carlsbad, CA, USA). Normal melanocytes were isolated from neonatal foreskins as previously described (eight) and maintained in Medium 254 supplemented with 0.2 mM CaCl2, 16 nM 12-tetradecanoylphorbol 13-acetate (TPA) and melanocyte growth factors (Cascade Biologics, Portland, OR, USA).
Assays for cell proliferation and senescence For the proliferation assay, melanocytes were plated in 96-well plates at B50% confluence at 2 days before the assay. Cells were incubated with a nucleoside analog of thymidine, EdU, for 60 min followed by fixation and staining for EdU-incorporated cells using the ClickiT EdU Assay kit (Invitrogen Inc). The proportion of EdU-positive cells was determined by counting cells under the fluorescent microscope in multiple view fields.
For the senescence assay, cells were plated in 12-well plates at B30% confluence at 2 days before the assay. Cells were fixed and incubated for different time periods (4 h to overnight, depending on the cell line) at 37 1C with the staining solution containing the X-Gal substrate (BioVision, Mountain View, CA, USA). The development of blue color was detected visually with a microscope. The proportion of positive cells was determined by counting the cells under the light microscope in multiple view fields. To visualize senescenceassociated heterochromatin foci, cells were fixed with 0.5% formaldehyde and stained with 4 0 ,6-diamidino-2-phenylindole as described previously (Denoyelle et al., 2006) . The proportion of the senescence-associated heterochromatin foci-positive cells was determined by counting the cells with fluorescent microscopy in multiple view fields.
Assay for C-MYC protein stability C-MYC protein stability was determined using pulse-chase labeling with Scysteine (300 mCi/ml, Perkin-Elmer, Waltham, MA, USA) in the cysteine-and methionine-free media for 3 h and 1 h, respectively. After that, cells were washed and incubated in media containing non-radioactive cysteine and methionine for 0, 20, 40 or 60 min. After completion of incubation, cells were harvested, lysed in immunoprecipitation buffer and total cellular extracts were immunoprecipitated with mouse anti-C-MYC monoclonal antibodies (C33, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Immunoprecipitated materials were separated on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and labeled C-MYC was quantified using STORM phospho-imager (Molecular Dynamics Storm 840, Cambridge Scientific, Watertown, MA, USA).
Lentiviral constructs and infection
Lentiviral infection protocols and vectors containing control shRNA, C-MYC shRNA, complementary DNAs of BRAF V600E , NRAS Q61R and HRAS G12V were described previously (Arnold and Sears, 2006; Denoyelle et al., 2006) . The pLKO-1 lentiviral vectors containing shRNAs specific for the human gene encoding PP2A-B56a were purchased from Sigma (St Louis, MO, USA).
Quantitative reverse transcription real-time-PCR
Total RNA was isolated from cells using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). Complementary DNA was prepared using the complementary DNA reverse transcription kit (Invitrogen Inc.). Quantitative reverse transcription realtime-PCR was performed on 7900HT Fast Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA) using TaqMan Universal Master Mix II (Applied Biosystems) and probes and PCR primers specific for human b-actin, human C-MYC or human PP2A-B56a genes. PCR data were analyzed using sequence detection software 2.4 (Applied Biosystems).
Immunoblotting and immunofluorescence
Antibodies were used against the following human proteins: p53, C-MYC, SKP2, CIP2A, ERK1/2 and ERK1/2-g from Santa Cruz Biotechnology (sc-99, sc-42, sc-7164, sc-80659, sc-93, sc-7383, respectively); C-MYC-Ser-62, PP2A-B56a and Fbw7 from Abcam (Cambridge, MA, USA) (ab78318, ab1084 and ab12292, respectively); p16 INK4A PIN1, USP28, from Cell Signaling Technology (Danvers, MA, USA) (4824, 3722, 4217 s); from SPP2A-C from BD Biosciences (San Jose, CA, USA) (bd-610555); and TRUSS from Proteintech (Chicago, IL, USA) (12606-1-AP). Membranes were developed using alkaline phosphatase-conjugated secondary antibodies and the Alpha-Innotech FluorChem HD2 imaging system (Alpha Innotech Corporation, San Leandro, CA, USA). Quantification of the signal was performed using the ImageQuant 2.0 program package. The background was calculated from an equivalent area in each lane and subtracted from the value for the protein signal in that lane.
TMAs, immunohistochemistry and statistical analysis
Three 1-mm tissue cores of formalin-fixed and paraffinembedded primary cutaneous tissue from patients with good prognosis (56 cores) or metastatic melanoma (167 cores) were precisely arrayed into paraffin blocks. Immunohistochemical staining was performed using the PP2A-B56a mouse monoclonal antibody (clone 23/B56a; BD Biosciences; dilution 1:50). Briefly, this procedure consisted of deparaffinization and rehydration followed by epitope retrieval in which the TMAs were immersed in Target Retrieval Solution (Dako, Carpinteria, CA, USA) and incubated with steam for 40 min. Incubation with PP2A-B56a antibodies was performed for 45 min and was followed by the serial application of biotinylated goat antimouse IgG (Jackson ImmunoResearch, West Grove, PA, USA), alkaline phosphatase-conjugated streptavidin (Invitrogen), and the Fast-Red Substrate System (Dako). Results were recorded as semiquantitative/ordered categorical, according to the American Society of Clinical Oncology Guideline Recommendations. The neoplastic cells for any given core were scored for (i) intensity of staining using the following scale: no staining (0), weak staining (1), moderate staining (2), strong staining (3). The Somers' D statistic (Newson, 2006) was used to assess the correlation between the intensity of immunohistochemical staining and tumor stage (primary or metastatic).
